On June 19, 2012, Generex Biotechnology Corporation (the "Company") held its Annual Meeting at the Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, Ontario, Canada. The following proposals were submitted to the stockholders at the Annual Meeting:

1. To elect six directors;

2. To ratify the appointment of MSCM LLP as independent public accountants for the year ending July 31, 2012; and

3. To conduct any other business as may properly come before the annual meeting or any adjournment or postponement thereof.

Only stockholders of record as of the close of business on May 2, 2012 were entitled to vote at the Annual Meeting. As of May 2, 2012, 343,474,558 shares of common stock of the Company were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 234,391,226 shares of common stock of the Company were represented, in person or by proxy, constituting a quorum.

The votes with respect to the proposals are set forth below.

(1) Elect the Directors of the Company to serve until the 2013 Annual Meeting:

The following nominees were elected as directors to serve until the 2013 Annual Meeting by the votes indicated below:

Name of Director Nominees      For       Withheld      Broker Non-Votes
John P. Barratt             40,622,565   8,395,269       185,373,392
Nola E. Masterson           38,992,342   9,166,992       185,373,392
Brian T. McGee              40,886,104   8,131,730       185,373,392
Mark A. Fletcher            40,615,873   8,401,961       185,373,392
James H. Anderson, Jr.      42,867,333   6,150,501       185,373,392
Eric Von Hofe, Ph.D.        44,045,601   4,972,233       185,373,392

(2) Ratification of the appointment of MSCM LLP as the Company's independent registered public accounting firm for the fiscal year ending July 31, 2012:

The proposal to ratify the appointment of MSCM LLP as the Company's independent registered public accountant for fiscal year ending July 31, 2012 was approved by the votes indicated below. There were no broker non-votes on this proposal.